Emapalumab (NI-0501) is a humanized monoclonal IFN-γ bound to its receptor. Emapalumab can be used in research of hemophagocytic lymphohistiocytosis (HLH)[1].
Emapalumab (NI-0501) impairs IFNcR1 and IFNc-Receptor-2 (IFNcR2) interaction induced by IFNc at the cell surface.
[1]. Vallurupalli M, et, al. Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosis. Blood. 2019 Nov 21;134(21):1783-1786.
















